| 2024-09-28 |
复牌提示：
2024-09-27 14:02:56 停牌，复牌日期 2024-09-27 14:07:56
|
| 2024-09-25 |
详情>>
拆分方案：
每10.0000合并分成1.0000股
|
| 2024-09-23 |
详情>>
股本变动：
变动后总股本477.08万股
变动原因 ▼▲
- 原因：
- a 1-for-10 reverse stock split of the Company’s common stock
|
| 2024-08-08 |
详情>>
业绩披露：
2024年中报每股收益-0.52美元,归母净利润-1866.9万美元,同比去年增长58.53%
|
| 2024-05-20 |
详情>>
业绩披露：
2024年一季报每股收益-0.29美元,归母净利润-976.5万美元,同比去年增长49.85%
|
| 2024-05-06 |
股东大会：
将于2024-06-27召开股东大会
会议内容 ▼▲
- 1.To elect six (6) directors to serve one-year terms expiring in 2025;
2.To approve a proposed amendment to the 2017 Equity Incentive Plan to increase the number of shares available for the grant of awards by 9,000,000 shares;
3.To ratify the appointment of Kesselman & Kesselman C.P.A.s, a member firm of PricewaterhouseCoopers International Limited, as our independent registered public accounting firm for the fiscal year ending December 31, 2024;
4.To transact such other business that is properly presented at the annual meeting and any adjournments or postponements thereof.
|
| 2024-04-15 |
详情>>
业绩披露：
2023年一季报每股收益-0.87美元,归母净利润-1947万美元,同比去年增长-385.66%
|
| 2024-04-15 |
详情>>
业绩披露：
2023年中报每股收益-1.63美元,归母净利润-4501.3万美元,同比去年增长-377.03%
|
| 2024-04-15 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-1.7美元,归母净利润-4873.8万美元,同比去年增长-351.61%
|
| 2024-04-15 |
详情>>
业绩披露：
2023年年报每股收益-1.91美元,归母净利润-5536.1万美元,同比去年增长-271.82%
|
| 2023-04-21 |
股东大会：
将于2023-06-08召开股东大会
会议内容 ▼▲
- 1.To elect six (6) directors to serve one-year terms expiring in 2024;
2.Approval of certain terms of the Second Amended and Restated Limited Liability Company Agreement (the “LLC Agreement”) entered into in connection with the Unit Purchase Agreement, dated as of November 4, 2022 (the “Unit Purchase Agreement”), by and among the Company, Morgenesis LLC, a subsidiary of the Company (“Morgenesis”), and MM OS Holdings, L.P. (“MM”), which grant certain rights to MM with respect to Morgenesis and the exercise by MM of its rights under the LLC Agreement, as disclosed in this proxy statement;
3.To ratify the appointment of Kesselman & Kesselman C.P.A.s, a member firm of PricewaterhouseCoopers International Limited, as our independent registered public accounting firm for the fiscal year ending December 31, 2023;
4.To approve by an advisory vote the compensation of our named executive officers, as disclosed in this proxy statement;
5.To approve by an advisory vote the frequency of holding an advisory vote on compensation of our named executive officers;
6.To transact such other business that is properly presented at the annual meeting and any adjournments or postponements thereof.
|
| 2023-03-22 |
详情>>
业绩披露：
2022年年报每股收益-0.59美元,归母净利润-1488.9万美元,同比去年增长17.53%
|
| 2022-11-10 |
详情>>
业绩披露：
2022年三季报(累计)每股收益-0.43美元,归母净利润-1079.2万美元,同比去年增长17.22%
|
| 2022-11-01 |
股东大会：
将于2022-12-15召开股东大会
会议内容 ▼▲
- 1.To elect six (6) directors to serve one-year terms expiring in 2023;
2.To ratify the appointment of Kesselman & Kesselman C.P.A.s, a member firm of PricewaterhouseCoopers International Limited, as our independent registered public accounting firm for the fiscal year ending December 31, 2022;
3.To transact such other business that is properly presented at the annual meeting and any adjournments or postponements thereof.
|
| 2022-08-15 |
详情>>
业绩披露：
2022年中报每股收益-0.38美元,归母净利润-943.6万美元,同比去年增长-227.87%
|
| 2022-05-23 |
详情>>
业绩披露：
2022年一季报每股收益-0.16美元,归母净利润-400.9万美元,同比去年增长-1730.59%
|
| 2022-01-28 |
详情>>
内部人交易：
Caplan Vered股份增加278191.00股
|
| 2021-10-19 |
股东大会：
将于2021-12-16召开股东大会
会议内容 ▼▲
- 1.To elect six (6) directors to serve one-year terms expiring in 2022;
2.To ratify the appointment of Kesselman & Kesselman C.P.A.s, a member firm of PricewaterhouseCoopers International Limited, as our independent registered public accounting firm for the fiscal year ending December 31, 2021;
3.To transact such other business that is properly presented at the annual meeting and any adjournments or postponements thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-03-09 |
财报披露：
美东时间 2021-03-09 盘前发布财报
|
| 2020-11-03 |
股东大会：
将于2020-11-18召开股东大会
会议内容 ▼▲
- 1.To elect six (6) directors to serve one-year terms expiring in 2021;
2.To ratify the appointment of Kesselman & Kesselman C.P.A.s, a member firm of PricewaterhouseCoopers International Limited, as our independent registered public accounting firm for the fiscal year ending December 31, 2020;
3.To approve by an advisory vote the compensation of our named executive officers, as disclosed in this proxy statement;
4.To transact such other business that is properly presented at the annual meeting and any adjournments or postponements thereof.
|
| 2019-10-08 |
股东大会：
将于2019-11-26召开股东大会
会议内容 ▼▲
- 1.To elect five directors to serve one-year terms expiring in 2020;
2.To approve a proposed amendment to the Company’s 2017 Equity Incentive Plan to increase the number of shares available for the grant of awards by 1,250,000 shares;
3.To approve an amendment to our Articles of Incorporation to authorize the Company to issue up to 10,000,000 shares of blank check preferred stock, par value $0.0001 per share, in one or more series as determined by our board of directors, with such rights, privileges, preferences and limitations as our board of directors may, in its sole discretion, determine;
4.To ratify the appointment of Kesselman & Kesselman C.P.A.s, a member firm of PricewaterhouseCoopers International Limited, as our independent registered public accounting firm for the fiscal year ending December 31, 2019;
5.To transact such other business that is properly presented at the annual meeting and any adjournments or postponements thereof.
|
| 2018-09-21 |
股东大会：
将于2018-10-23召开股东大会
会议内容 ▼▲
- 1.Election of five director nominees named in the Proxy Statement;
2.Approval of certain terms of the Stockholders’ Agreement entered into in connection with the Stock Purchase Agreement dated June 28, 2018, by and among the Company, Masthercell Global Inc., a subsidiary of the Company (“Masthercell Global”), and GPP-II Masthercell, LLC (“GPP-II”), which grant certain rights to GPP-II with respect to Masthercell Global and the exercise by GPP-II of its rights under the Stockholders’ Agreement, each as described in the Proxy Statement;
3.Approval of the potential future issuance of the Company’s common stock upon the exercise of an option by GPP-II to exchange preferred stock of Masthercell Global pursuant to the terms of the Stockholders’ Agreement without the need for any limitation or cap on issuances as required by and in accordance with Nasdaq Listing Rule 5635;
4.Ratification of the appointment of Kesselman & Kesselman C.P.A.s, a member firm of PricewaterhouseCoopers International Limited, as the Company’s independent registered public accounting firm for the fiscal year ending November 30, 2018;
5.To transact such other business as may properly come before the meeting or any adjournments or postponements thereof.
|